Company performance
Add to research
Current Price
as of Mar 25, 2025$280.96
P/E Ratio
N/A
Market Cap
$36.55B
Description
Add to research
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Metrics
Add to research
Overview
- HQCambridge, MA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerALNY
- Price$280.96-3.35%
Trading Information
- Market cap$36.55B
- Float95.60%
- Average Daily Volume (1m)914,044
- Average Daily Volume (3m)757,150
- EPS-$2.18
Company
- Revenue$2.25B
- Rev growth (1yr)22.97%
- Net income-$278.16M
- Gross margin85.62%
- EBITDA margin-5.35%
- EBITDA-$120.21M
- EV$30.09B
- EV/Revenue13.38
- P/EN/A
- P/S15.95
- P/B541.47
- Debt/Equity4,089.28
Documents
Add to research
SEC Filings
Factset Street Account
Earnings Calls
Factset